Background: Inflammation, measured by high-sensitivity C-reactive protein (hsCRP), is linked to adverse reproductive outcomes. However, prevalence and predictors of low-grade inflammation are poorly understood among reproductive age women. Therefore, the current aim was to characterize: (i) the prevalence of elevated hsCRP and (ii) whether the association of various demographic, anthropometric, life style, and metabolic characteristics with higher hsCRP varies across populations of reproductive age women with varying risk profiles for adverse reproductive outcomes. Methods: Bivariate analysis of characteristics among women ages 18-40 having hsCRP <2.0 vs. ≥2.0 mg/L in the BioCycle Study (N = 259), the Effects of Aspirin in Gestation and Reproduction Trial (EAGeR) (N = 1228), and the National Health and Nutrition Examination Survey (NHANES; N = 2173) were conducted. Multivariable regression analysis estimated the association of all characteristics to hsCRP within each cohort. Results: Prevalence of hsCRP≥2 mg/L ranged from 20 to 40%. Age, BMI, waist circumference, blood pressure, lipids, glucose, and insulin were frequently higher in women with hsCRP ≥2 mg/L. In multivariable models, however, only adiposity (BMI, waist circumference) was independently associated with hsCRP within all three cohorts. Some variables showed cohort-specific associations with higher hsCRP: white race (EAGeR), higher fasting glucose (BioCycle), and lesser education and employment (NHANES). The total characteristics explained 28-46% of the variation in hsCRP across the three cohorts. Conclusions: Low-grade inflammation was common, including among predominantly non-obese women, affecting from 20 to 40% of reproductive age women. Given the potential to reduce inflammation through inexpensive, widely available therapies, examination of the impact of chronic inflammation on reproductive and pregnancy outcomes, as well as preventive interventions, are now needed.
inflammation, specifically resulting in a 31% increase in the clinical pregnancy rate in women with hsCRP ≥2 mg/L at study entry. 12 However, the prevalence of low-grade inflammation among women of reproductive potential, as opposed to middle-aged adults at risk for cardiovascular disease, and the factors which may contribute to moderately elevated hsCRP in this population are uncertain. Thus, in the current era of personalized medicine and available anti-inflammatory treatments, the goal of the present investigation was to identify presently undetected groups susceptible to low-grade inflammation, a potential treatment target to ultimately improve fertility and pregnancy health. Specifically, this study aimed to exploit data from three unique cohorts of reproductive age women with differing risk profiles for adverse reproductive and pregnancy outcomes: (i) healthy, reproductive age women not actively attempting pregnancy but who are at risk of becoming pregnant because of lack of oral contraception use and variable sexual activity, especially given that roughly half of pregnancies in the U.S. are not specifically planned; 13 (ii) healthy, reproductive women actively attempting spontaneous pregnancy but with a history of pregnancy loss, a cohort particularly relevant to a large proportion of women trying to conceive since up to 20-30% of all conceptions end in loss; 14, 15 and (iii) a population-representative sample of reproductive age women, including with morbidities and race-ethnic distributions underrepresented in the previous two selected populations. Therefore, within each cohort described above, the aim of the present investigation was to: (i) characterize the prevalence of moderately elevated hsCRP and (ii) evaluate whether the association of demographic, anthropometric, life style, and metabolic characteristics with higher hsCRP varies across these cohorts of women.
Methods
Three distinct cohorts of reproductive age women were investigated: (i) 259 regularly menstruating, healthy women who were not using hormonal contraception and not attempting pregnancy (the BioCycle Study, 2005-2007); 16 (ii) 1228 regularly menstruating, healthy women who were not using hormonal contraception and were actively attempting pregnancy with a history of 1-2 prior pregnancy losses as part of a clinical trial of low-dose aspirin (the Effects of Aspirin 18 For each cohort, the design, methods, and participant characteristics have been previously described. Study characteristics and methods that are relevant to the present analysis are summarized below. Table S1 contains a detailed report of betweencohort differences in inclusion and exclusion criteria. Importantly, to assess the endogenous factors associated with higher hsCRP among reproductive aged women, two of the three cohorts employed blood sampling during the menses phase of the menstrual cycle, as hsCRP has been shown to fall approximately 0.30 mg/L from menses to ovulation. 19 Another important source of higher hsCRP consistently noted in women that was excluded from this analysis, is the use of hormonal medication, where a difference of 1.25 mg/L has been noted between hormone replacement therapy users vs. non-users. 20 hsCRP may also vary across season, with higher concentrations in winter to spring, 21, 22 but it remains unclear whether this is attributable to seasonal variation in exposure to infection (e.g. cold and flu season), variation in vitamin D, 23 or something inherent to season such as photoperiod or temperature. Regardless, this study was not able to account for season as a potential source of within-woman variation. For the BioCycle Study, 259 women from Western New York were recruited to participate for two menstrual cycles in a prospective study of cyclic changes in oxidative stress biomarkers, antioxidants, and endogenous reproductive hormones. Participants were regularly menstruating (cycles 21-35 days), age 18-44 years, with self-reported body mass index (BMI) 18-35 kg/m 2 at screening. BioCycle study exclusion criteria included use of oral contraceptives or short-acting hormonal treatments (e.g. patch, ring) during the preceding 3 months, use of longer acting hormonal contraceptive medication (i.e. DepoProvera, Norplant, intrauterine device) in the preceding 12 months, current use of vitamin and mineral supplements or prescription medications, pregnancy or breast feeding in the preceding 6 months, currently attempting pregnancy, diagnosis of polycystic ovary syndrome (PCOS), infertility, or chronic medical conditions, and recent history of infections. The Health Sciences Institutional Review Board at the University at Buffalo approved the study; written informed consent was obtained from all participants. The EAGeR trial enrolled 1228 women at four U.S. medical centres in a randomized trial of preconception-initiated, daily low-dose aspirin and livebirth. Participants were regularly menstruating (cycles 21-42 days), age 18-40 years, and were actively attempting natural conception with a history of 1-2 documented pregnancy losses. Exclusion criteria included any indication or contra-indication for lowdose aspirin; diagnosis of PCOS, infertility, or chronic medical condition; and chronic use of NSAIDs. Institutional Review Board approval was obtained at each of the study sites, and all participants provided written informed consent. The trial was registered with ClinicalTrials.gov (NCT00467363).
The NHANES assesses the health and nutritional status of U.S. adults and children, obtaining a sample that is representative of the U.S. civilian, non-institutionalized population. To obtain data contemporaneous with the BioCycle and EAGeR studies, the present analysis used cross-sectional data from the 2005-2006 and 2007-2008 waves of NHANES. For the present analysis, the following exclusions were applied to the publicly available dataset (downloaded July 20, 2015): men, women ages <18 or >40 years, women who were pregnant as indicated either by self-report or positive result from a spot-urine pregnancy test, and women currently using hormonal contraception. These exclusions resulted in 1507 total women available for this study. The present analysis accounted for the NHANES multi-stage sampling scheme and our additional inclusion criteria (women age 18-40 years who are not currently pregnant and not using hormonal contraception), producing results generalizable to U.S. women who meet these inclusion criteria. NHANES is conducted by the National Center for Health Statistics of the U.S. Centers for Disease Control and Prevention (CDC). The CDC Institutional Review Board approved the study and all participants provided informed consent. 18 
Data collection
The BioCycle study
The study baseline visit occurred on day 2 of the menstrual cycle (during menses). At this visit, demographic, reproductive history, and health behaviour information was gathered through questionnaires, and fasting blood samples and anthropometric measures were collected by study staff.
The EAGeR trial
The study randomization visit (pre-aspirin treatment) occurred on day 2-4 of the menstrual cycle; questionnaires elicited data on participant demographics, reproductive history, and health behaviours. Anthropometric measures and untimed (i.e. random, majority non-fasting) blood samples were collected by study staff.
NHANES
At a study visit that was not timed to the menstrual cycle, trained interviewers collected data on participant demographics, medical and reproductive histories, current and past use of contraceptives, and health behaviours. Also, anthropometric measures and non-fasting blood samples were collected by study staff. Some participants (n = 579) were selected to attend a morning medical examination visit where a fasting blood sample was collected.
Biospecimen analysis
The BioCycle study Serum hsCRP was measured using a chemiluminescent immunoassay (IMMULITE 2000 platform) sensitive to 0.3 mg per litre. Fasting serum total cholesterol, high-density lipoprotein cholesterol (HDL) cholesterol, and triglycerides were determined by an auto chemistry analyser. Low-density lipoprotein cholesterol (LDL) cholesterol was determined using the Friedewald formula. 24 Fasting plasma glucose was assayed using a hexokinase-based methodology on a Beckman LX20 autoanalyser (Beckman Coulter, Brea, CA, USA). Fasting serum insulin was measured using a solid-phase competitive Chemiluminescent Enzymatic Immunoassay by Specialty Laboratories on the DPC Immulite 2000 analyser (Siemens, Tarrytown, NY, USA).
The EAGeR trial
Serum hsCRP was measured using an immunoturbidimetric assay using Roche COBAS 6000 autoanalyser, with a limit of detection of 0.15 mg/L (Roche Diagnostics, Indianapolis, IN). Random total triglyceride, total cholesterol, high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL) concentrations were ascertained using Roche COBAS 6000 chemistry analyser (Roche Diagnostics, Indianapolis, IN). Random plasma glucose was measured by a hexokinase-based assay using a Roche COBAS 6000 chemistry analyser. Random serum insulin was measured by sandwich immunoassay method using a Roche COBAS 6000 chemistry analyser (Roche Diagnostics).
NHANES
Serum hsCRP was measured by latex-enhanced nephelometric assay on the Dade Behring Nephelometer II Analyzer System (Dade Behring Diagnostics, Inc., Somerville, NJ) with a limit of detection of 0.20 mg/L. Fasting total cholesterol and triglycerides were measured enzymatically in serum using either a Hitachi 717 or Hitachi 912 (Hitachi Global Storage Technologies, San Jose, CA) with a range of 3-800 mg/dL and 4-3000 mg/dL, respectively. HDL was measured directly using either a Hitachi 717 and 912 with a detection range of 3-120 mg/dL. LDL cholesterol was calculated using the Friedewald formula. 24 Fasting glucose was measured by hexokinase-mediated reaction with measurement of NADPH at 340 nm using a Roche/Hiatchi Analyzer (Roche Diagnostics, Indianapolis, IN). Insulin was measured with human insulin immunoassay using a SPECTRAmax TM 250 Microplate Spectrophotometer (Molecular Devices, Sunnyvale, CA) with a detection limit of <1 mU/L.
Statistical analysis
In each of the three studies, descriptive statistics of potentially relevant demographic, health, life style, and reproductive history characteristics were calculated (including the total cohort for each: 259 for BioCycle, 1228 for EAGER, 1507 for NHANES). Then, bivariate analysis of each of these characteristics was conducted in women with lower versus higher hsCRP (<2 mg/L vs. 2-9.99 mg/L). Cut-points of hsCRP with demonstrated clinical utility for predicting cardiovascular disease risk in middle-aged adults define high risk as hsCRP ≥3 mg/L; 25 however, a lower cut-point of hsCRP ≥2 mg/L has been used to define 'high' hsCRP among adults considered to have low risk of cardiovascular disease (perhaps a more relevant population to presumably healthy premenopausal women). 26, 27 Furthermore, hsCRP 2-9.9 mg/L was the range that was associated with lower pregnancy rates in the EAGeR trial. 12 Women with hsCRP ≥10 mg/L were excluded from bivariate analyses, as well as regression modelling described below, as hsCRP ≥10 mg/L prompts retesting in clinical cardiovascular risk assessment and is consistent with acute phase inflammatory events (e.g. infection), as opposed to chronic low-grade inflammation. 28 Any hsCRP values identified as below the assay limit of detection were substituted with the assay limit of detection divided by the square root of 2. Characteristics among women with lower (<2 mg/L) versus higher (2.0-9.99 mg/L) hsCRP (Table 2) were compared with Student's t-test for normally distributed continuous variables, Mann-Whitney U test for serum biomarkers which were not normally distributed, and Chi-square test for categorical variables.
In each cohort a generalised linear model of logtransformed hsCRP was fit as a function of all demographic, health, life style, and reproductive history characteristics to examine the association of each characteristic to hsCRP across the three cohorts. The change in hsCRP per one unit change in a given variable (excluding log-transformed biomarkers) may be interpreted as a percent change in hsCRP (e.g. an increase in one BMI unit would result in a 9% increase in hsCRP in the BioCycle cohort). For independent variables which are log-transformed (i.e. lipid biomarkers, glucose, insulin), the percent change in hsCRP is expressed per one percent change in the independent variable (e.g. for each one percent increase in glucose, hsCRP increases by 1.93 percent in the BioCycle cohort). In each cohort, a multiple imputation procedure used a Markov chain Monte Carlo Method 29 to generate 20 complete datasets for all variables needed for the analysis (hsCRP and predictor variables, including demographics, health, life style, and biomarkers). The multiple imputation model that was applied to the NHANES data also included variables denoting NHANES cluster and stratum. Among BioCycle participants, no variable was missing greater than 1%, except parity which was missing for 6 women (2.4%); missingness for any variable was less than 4% in the EAGeR cohort except education which was missing for 12.5% (n = 146) women; and among NHANES participants, missingness for any variable was less than 10% except for income (10.2%), diastolic blood pressure (11.6%), systolic blood pressure (16.6%), smoking status (19.7%), and physical activity level (53.7%). Biomarkers included in the regression models also were log transformed for normality. Among the eligible NHANES participants, 579 women with fasting samples were included in the regression analysis. Analyses were conducted using SAS software (version 9.4; SAS Institute, Inc, SAS Inc., Cary, NC, USA). For NHANES analyses, appropriate sampling weights and variables to account for the additional exclusion criteria were applied. 30 
Results
Across the three cohorts, median (interquartile range) hsCRP ranged from 0.8 (0.4, 1.9) mg/L in the BioCycle Study to 1.4 (0.4, 3.9) mg/L in NHANES women. The prevalence of higher hsCRP (2.0-9.99 mg/L) was 20% in the BioCycle Study, 30% in the EAGeR trial cohort, and was 40% among women in NHANES (Table 1) . In bivariate analyses, certain factors were generally positively associated with higher hsCRP in all three cohorts (Table 2) , including older age, higher BMI, larger waist circumference, higher blood pressure, higher lipids, and higher glucose and insulin concentrations. Reproductive history characteristics were inconsistently associated with higher hsCRP, where nearly twice higher parity was associated with having higher hsCRP in the BioCycle study, and earlier age at menarche was associated with higher hsCRP in the NHANES cohort. Interestingly, smoking was only associated with higher hsCRP in NHANES; however, overall smoking prevalence was relatively low in the BioCycle and EAGeR cohorts compared to NHANES.
In multivariable models including all characteristics, adiposity measured by either BMI or waist circumference was independently associated with higher hsCRP within all three cohorts (Table 3) . Specifically, each unit increase in BMI was associated with a 4-9% increase in hsCRP; this would translate to an increase in hsCRP of 0.3-0.7 ng/mL with an increase in five BMI units (a range separating BMI obesity categories), assuming a starting hsCRP concentration of 1.5 mg/mL. Also, some variables showed cohort-specific associations with higher hsCRP, such as white race in EAGeR women, though the estimate for white vs. non-white race was similar in the smaller BioCycle cohort. Also, higher fasting glucose was linked to higher hsCRP, but only in BioCycle. Women who were currently employed and who had completed at least a high school education had lower mean hsCRP in the NHANES cohort, but not in the other two cohorts. Of note, all BioCycle participants eligible for the linear regression analysis had at least a high school education. In contrast to the bivariate analyses, multivariable-adjusted models showed no independent association of hsCRP with age, nor with variables closely associated with age such as parity and marital status, nor was hsCRP associated with any lipid biomarker in any cohort.
The set of variables explained 28% of the variation in hsCRP among EAGeR trial participants, 34% in the BioCycle participants, and 46% in NHANES participants (Table 3) .
Comment
This study examined the prevalence and predictors of moderately elevated hsCRP (2-9.99 mg/L), as a marker of low-grade inflammation, across three distinct populations of reproductive-age women, and found that inflammation was common. Specifically, the prevalence ranged from 20 to 40%, with lower prevalence among cohorts selected to be healthy, including having lower adiposity, and higher prevalence in the general population. Adiposity as measured by BMI or waist circumference was independently associated with higher hsCRP in all three populations, even after considering multiple demographic, health, life style, and reproductive history characteristics. Still, it is notable that low-grade inflammation was present in 1 in 5 women among the BioCycle cohort selected to be healthy and predominantly normal weight. Furthermore, the total variance in hsCRP explained in reproductive age women ranged from 28 to 46%, indicating other unmeasured factors likely contribute to lowgrade inflammation among this population.
Moderately elevated hsCRP was prevalent and increased with decreasing exclusivity of the study populations examined. Specifically, in the NHANES cohort, designed to be nationally representative, the prevalence of moderately elevated hsCRP was 40%, whereas this rate was 20% among BioCycle participants. No generally accepted thresholds are established for defining elevated hsCRP in reproductive age women with relevance to optimal fertility and pregnancy health, and few studies have included reproductive age women when characterizing hsCRP. Therefore, it is challenging to compare the prevalence of hsCRP ≥2 mg/L characterized here to other © 2017 This article is a U.S. Government work and is in the public domain in the USA.
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High, hsCRP 2-9. studies. However, an earlier study of four large U.S. cohorts of apparently healthy adults reported a median hsCRP of 1.52 mg/L in women not using exogenous hormones. This is similar to the median hsCRP of 1.4 mg/L in the population-representative NHANES cohort reported here, though these prior studies represented predominantly Caucasian participants and included adults ages 40-84, as opposed to age 18-40 included in NHANES here. 5 Other cohorts of U.S. adults ages 30-65 exhibited median hsCRP of 3.2 mg/L in white women and 3.5 mg/L black women, well above our observations, though normal weight participants had median hsCRP of 1.7 mg/L in both racial groups. NHANES cohort excluding women using hormonal contraception; use of hormonal contraceptives was an exclusion criteria for BioCycle and EAGeR. The present analysis accounted for the NHANES multi-stage sampling scheme and our additional exclusion criteria with appropriate samplings weights and variables, producing results generalizable to U.S. women who meet these inclusion criteria.
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Comparing our estimated median hsCRP levels with results from other countries, our estimated median values are consistent with a study of reproductive-age Australian women after accounting for exogenous oestrogen use, 32 but values observed here are higher than reports from premenopausal women in Denmark 33 and Norway. 34 Besides differences in body composition, differences in diet and life style could contribute to differences in hsCRP levels across nations. Lastly, the prevalence of hsCRP ≥10 mg/L observed in this study was similar to that observed in other studies, further supporting this range of hsCRP as being predominantly attributable to transient acute events (i.e. infection) and not chronic, systemic inflammation. 28, 32 Our finding of a positive relationship between hsCRP and adiposity agrees with prior studies in other populations. Certainly the most consistently linked health factor to higher hsCRP is central body fat distribution, 35 and BMI, 32 as observed also in each of the three cohorts of women examined here, and independent of the multiple other factors examined. Though multiple metabolic markers, including lipids, glucose, and insulin, were also elevated in women with higher hsCRP, nearly all these associations disappeared when modelled simultaneously with adiposity and other factors. Of note, higher socio-economic status, specifically employment and higher educational attainment, was associated with lower hsCRP in NHANES, consistent with prior studies. 36, 37 Observing this effect only among NHANES is likely attributable to the greater diversity in socio-economic status among this nationally representative sample, evidenced by the greater variation in educational attainment than was seen in either of the highly selected populations in the EAGeR trial or BioCycle Study. Also, in the BioCycle population having the lowest BMI and waist circumference, only BMI was independently associated with hsCRP with somewhat larger estimates than in the other cohorts and with no association between hsCRP and waist circumference. In contrast, in the cohort of highest overall adiposity (NHANES), the beta coefficient for waist circumference was relatively larger and the estimate for BMI smaller than the other cohorts. Thus, perhaps in leaner women BMI is a more informative predictor of hsCRP, whereas in women with greater adiposity, waist circumference is more informative to systemic inflammation. Similarly, fasting glucose was only independently related to hsCRP among the leaner, younger BioCycle participants, but was not informative in models of hsCRP in the other cohorts; though speculative, this finding may suggest that inflammation-associated dysmetabolism precedes development of excess adiposity with advancing age. Interestingly, white race (compared to non-white) was associated with increasing hsCRP among the EAGeR cohort, in contrast to prior reports indicating higher hsCRP in black women. 38, 39 Given the low proportion of non-white participants (approx. 5%) in the EAGeR cohort and lack of corroboration in the other, more racially diverse cohorts included here, this is likely a chance finding. Collectively, these data indicate that overarching predictors of hsCRP appear similar among reproductive age women as in other populations, with the exception of age, which may be less relevant to chronic inflammation in younger women within a narrow age range as opposed to studies of all adult ages showing an positive relationship between age and hsCRP. 32 Another implication of our study is that further research on a broader range of factors is still needed to identify other contributors to chronically elevated hsCRP in healthy, reproductive age women, as among the two populations of selected women with lower rates of obesity and no oral contraceptive use, the demographic, health, life style, and reproductive characteristics explained less of the variation in hsCRP than they did in a nationally representative sample of reproductive-age women. Potential candidates not assessed here may include nutrition, 40, 41 oral health or other chronic localized infection, 1 as well as potentially less explored factors such as psychological stress or pollution. Identifying the contribution of these alternative factors could aid in the development of preventive efforts. Given that moderately elevated hsCRP, which was significantly associated with diminished pregnancy rate, 12 was prevalent (20-40%) even among cohorts selected to be healthy, and moreover in the BioCycle cohort also to be of predominantly normalweight, it remains important to interrogate other potential causes of chronic low-level inflammation in reproductive age women. Especially given that safe and effective anti-inflammatory treatments are available and have been applied in cardiovascular medicine, further investigation of the role of inflammation and anti-inflammatory treatments in the context of improving fertility and pregnancy health is warranted. Limitations of this study include that the NHANES hsCRP measurements were not timed to the menses phase of the menstrual cycle, when hsCRP is reportedly highest, as was done in the other two cohorts. This difference potentially contributed to greater hsCRP variability, inter-cohort and within NHANES, and underestimation of higher hsCRP in the NHANES cohort. 19 Furthermore, though hsCRP is a common clinical measure and all three studies utilized high-sensitivity hsCRP assays, differences in assay platforms may have impacted comparability across cohorts. Two of these three platforms were compared previously, 42 indicating that agreement between the IMMULITE platform (BioCycle) and the nephelometer (NHANES) was excellent at higher ranges of hsCRP (2-9.9 mg/L) but the IMMULITE platform used in BioCycle may produce somewhat higher values than in NHANES at the low range of hsCRP (<2 mg/L; e.g. 0.3 mg/L for nephlometer compared to 0.7 mg/L for IMMULITE, 0.9 mg/L for nephlometer vs. 1.3 mg/L for IMMULITE). Given that the lowest overall hsCRP concentrations were observed in BioCycle on the IMMULITE platform and such assay differences were only apparent below the cut-point of the low hsCRP category, it is unlikely that such assay variation was responsible for our findings in Tables 2 and 3 . Because the hsCRP reported values tended to be lowest in BioCycle, and its method of measurement apparently produces slight over-estimates compared to what was used in NHANES, actual differences across cohorts in the rates of higher hsCRP may be larger than reported here. Given the consistent relationship observed here and elsewhere between hsCRP and body mass, more specific measures of adiposity (e.g. from dual energy x-ray absorptiometry) would be useful to better examine these associations and should be considered in future studies. Also of note, this study assessed cross-sectional correlations and does not intend to establish causality. All three cohorts had rigorous quality control of the hsCRP assay and other variables, a large sample size, and low frequency of missing data. Our data provide the most comprehensive characterization of hsCRP in reproductive age women to date, including three separate populations which uniquely characterize women of reproductive potential in the U.S., and reveals consistent evidence for a relationship between adiposity and inflammation, independent of other demographic, metabolic, and health history variables. Of note, low-grade inflammation in this population was common, including among predominantly non-obese women, affecting from 20 to 40% of women of reproductive age. Given the great potential to reduce inflammation through inexpensive, widely available therapies, such as aspirin, statins, and non-steroidal anti-inflammatory drugs, expanded examination of the impact of chronic, low-grade inflammation prior to pregnancy on subsequent reproductive and pregnancy outcomes is needed. Establishing such relationships will ultimately aid in identifying appropriate preventive and treatment approaches to improve reproductive and pregnancy outcomes among reproductive age women.
